Pharmaceuticals, Biotechnology & Life Sciences

FDA review of Natera’s high‑sensitivity urine test for bladder‑cancer recurrence promises earlier detection, less invasive monitoring, and potential cost savings for patients and payers.

GSK cuts up to 350 R&D jobs yet boosts investment, showing its focus on oncology, immunology and rare‑disease breakthroughs amid portfolio gains and regulatory wins.

FDA accepts Galderma’s RelabotulinumtoxinA BLA resubmission, clearing the way to U.S. launch and boosting market share for anti‑wrinkle therapy.

Teva partners with Will Forte for Huntington’s disease awareness, amid earnings release and a strategy to boost rare‑disease access while managing patent cliffs.

Institutional investors back Waters Corp as it expands digital chemistry and service‑based revenue, positioning itself for growth in the $1.3 bn global HPLC market.

Amgen’s latest investor activity shows institutional confidence amid a downgrade, highlighting pipeline strengths, pricing pressures and patent risks.

Discover how Eisai’s EMA IV‑maintenance and FDA SC‑autoinjector approvals could improve Alzheimer’s therapy access, boost patient adherence, and expand market reach.

Biogen’s LEQEMBI IQLIK subcutaneous autoinjector gains FDA priority review—boosting early Alzheimer’s access, patient adherence, and investor confidence.

West Pharmaceutical Services hits $237 on NYSE as institutional buyers boost confidence in its high‑value packaging and drug delivery innovations.

Sanofi’s Phase III data for amlitelimab and OX40L could unlock $900 m+ in revenue, driving a shift toward value‑based contracts and boosting its competitive edge in dermatology and rheumatology.